DISCO Pharma’s Surfaceome Technology Unlocks Novel Cancer-Selective Targets

Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.